Efficacy of Olaparib (ola) Plus Abiraterone (abi) Vs Placebo (pbo) Plus Abi in the Non-Brca Mutation (non-Brcam) Subgroup of Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mcprc) in the Propel Trial

Mehra, N.Clarke, N. W.Armstrong, A. J.Oya, M.Shore, N. D.Procopio, G.Guedes, J. D. C.Arslan, Çağatay2023-12-262023-12-2620230923-75341569-8041https://doi.org/10.1016/j.annonc.2023.09.2753https://hdl.handle.net/20.500.14365/5005Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) -- OCT 20-24, 2023 -- Barcelona, SPAIN[No abstract available]eninfo:eu-repo/semantics/openAccessEfficacy of Olaparib (ola) Plus Abiraterone (abi) Vs Placebo (pbo) Plus Abi in the Non-Brca Mutation (non-Brcam) Subgroup of Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mcprc) in the Propel TrialConference Object10.1016/j.annonc.2023.09.2753